Data Provided by Refinitiv. Minimum 15 minutes delayed.
–
Summary ToggleIntellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
Jun 23, 2021 9:00 AM EDT
Intellia Therapeutics 2021 Annual Meeting of Shareholders
